Patents Assigned to Juridical Foundation the Chemo-Sero-Therapeutic Research Institute
-
Patent number: 6881721Abstract: The present invention provides a pharmaceutical composition for treatment and prevention of hemorrhage associated with blood coagulation disorders, comprising activated Factor VII (FVIIa) and Factor X (FX) as an active ingredient. The pharmaceutical composition of the present invention contains no components causative side effects, is safe, highly efficacious, and easy to manage hemostasis. The pharmaceutical composition can be used for hemostatic management of patients suffering from hemorrhage associated with blood coagulation disorders, for example, disorders (including deficiency) of blood coagulation factors, especially caused by inhibitors (antibodies) against blood coagulation factors.Type: GrantFiled: December 21, 2000Date of Patent: April 19, 2005Assignee: Juridical Foundation the Chemo-Sero-Therapeutic Research InstituteInventors: Yasushi Nakatomi, Kazuhiko Tomokiyo, Tatsuya Araki, Kaori Teshima, Tomoko Watanabe, Tomohiro Nakagaki
-
Patent number: 6869934Abstract: The present invention relates to a method for purifying a calcium ion-binding protein by cation exchange chromatography. The present invention provide a method for isolating and purifying a calcium ion-binding protein in a simple and efficient manner from a liquid sample containing a calcium ion-binding protein and contaminants without any pretreatment such as addition of a chelating agent. More specifically, the present invention relates to a method for purifying a calcium ion-binding protein which comprises contacting said protein with a cation exchange carrier in the presence of calcium ions to let the said protein be adsorbed to the carrier, and after washing, eluting said protein, and to a calcium ion-binding protein having substantially no contaminants obtained by the method of the present invention.Type: GrantFiled: July 18, 2001Date of Patent: March 22, 2005Assignees: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute, Kowa Company, Ltd.Inventors: Hiroshi Mizokami, Shinichi Furukawa, Keishin Sugawara, Tatsufumi Onchi, Kazuhiro Komatsu, Satoshi Koyanagi, Hideo Yoshizaki
-
Patent number: 6855319Abstract: The present invention provides a gene encoding a protein from merozoite of Babesia caballi, a recombinant protein of Babesia caballi, and an antibody capable specifically binding to a 48 kDa protein of rhoptry of Babesia caballi merozoite. In accordance with the present invention, it is possible to stably prepare the 48 kDa protein of rhoptry of Babesia caballi and the gene encoding said protein in a large amount with the recombinant DNA technique. The present invention also provides a method for diagnosing equine babesiasis which comprises either specifically detecting anti-Babesia caballi antibody present in equine blood by using the recombinant protein of present invention as an .antigen or detecting the presence of Babesia caballi merozoite in equine blood by using the antibody of the present invention.Type: GrantFiled: August 13, 1999Date of Patent: February 15, 2005Assignees: Juridical Foundation the Chemo-Sero-Therapeutic Research InstituteInventors: Hiromi Ikadai, Ikuo Igarashi, Naoyoshi Suzuki, Hideyuki Nagasawa, Kozo Fujisaki, Takeshi Mikami
-
Publication number: 20040254361Abstract: The present invention provides a gene encoding a protein from merozoite of Babesia caballi, a recombinant protein of Babesia caballi, and an antibody capable specifically binding to a 48 kDa protein of rhoptry of Babesia caballi merozoite. In accordance with the present invention, it is possible to stably prepare the 48kDa protein of rhoptry of Babesia caballi and the gene encoding said protein in a large amount with the recombinant DNA technique. The present invention also provides a method for diagnosing equine babesiasis which comprises either specifically detecting anti-Babesia caballi antibody present in equine blood by using the recombinant protein of present invention as an antigen or detecting the presence of Babesia caballi merozoite in equine blood by using the antibody of the present invention.Type: ApplicationFiled: June 9, 2004Publication date: December 16, 2004Applicants: Takeshi MIKAMI, JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTEInventors: Hiromi Ikadai, Ikuo Igarashi, Naoyoshi Suzuki, Hideyuki Nagasawa, Kozo Fujisaki, Takeshi Mikami
-
Patent number: 6825036Abstract: A novel MDCK-derived cell line (B-702) is provided that can be grown in the absence of fetal calf serum and in suspension culture for allowing a tank culture on the production scale and needs no carrier in suspension culture, as well as a process for producing virus for vaccine by using said cell line in a low-cost, highly safe and stable manner.Type: GrantFiled: September 3, 2002Date of Patent: November 30, 2004Assignee: Juridical Foundation the Chemo-Sero-Therapeutic Research InstituteInventors: Keiichi Makizumi, Kanako Masuda, Yoichiro Kino, Sachio Tokiyoshi
-
Patent number: 6566097Abstract: A novel feline cytokine protein having the activity to enhance the cytotoxic activity of feline cytotoxic T lymphocytes, a DNA sequence coding for said protein, a recombinant DNA for expressing said protein, an expression vector comprising said recombinant DNA, a transformant which is transformed with said expression vector, a process for preparing said protein by culturing said transformant, and an antibody against said protein are provided. The novel feline cytokine protein of the present invention is a heterologous dimer comprising FLAF p35 and FLAF p40 and can be used for treating feline infectious diseases such as feline herpes virus type 1 (FHV-1) or feline calicivirus (FCV).Type: GrantFiled: February 22, 2002Date of Patent: May 20, 2003Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Takayuki Imamura, Hiroaki Maeda, Takeshi Fujiyasu, Yoshitaka Imagawa, Sachio Tokiyoshi
-
Patent number: 6518045Abstract: A novel feline cytokine protein having the activity to enhance the cytotoxic activity of feline cytotoxic T lymphocytes, a DNA sequence coding for said protein, a recombinant DNA for expressing said protein, an expression vector comprising said recombinant DNA, a transformant which is transformed with said expression vector, a process for preparing said protein by culturing said transformant, and an antibody against said protein are provided. The novel feline cytokine protein of the present invention is a heterologous dimer comprising FLAF p35 and FLAF p40 and can be used for treating feline infectious diseases such as feline herpes virus type 1 (FHV-1) or feline calicivirus (FCV).Type: GrantFiled: April 30, 1999Date of Patent: February 11, 2003Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Takayuki Imamura, Hiroaki Maeda, Takeshi Fujiyasu, Yoshitaka Imagawa, Sachio Tokiyoshi
-
Publication number: 20030027987Abstract: A novel peptide obtained from Haemophilus paragallinarum has been found useful for preventing avian infectious coryza. This polypeptide induces production of hemagglutination-inhibition antibody and prevents infection and onset of avian infectious coryza. The invention further provides a gene coding for the polypeptide, a recombinant vector for expression of this gene, a host transformed with this vector, a process for preparing the polypeptide in a host, a vaccine for avian infectious coryza comprising the polypeptide as an active ingredient, a monoclonal antibody obtained using the polypeptide as an immunogen, and a diagnostic agent and a therapeutic agent for avian infectious coryza using the peptide and the antibody.Type: ApplicationFiled: July 11, 2002Publication date: February 6, 2003Applicant: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Eiji Tokunaga, Masashi Sakaguchi, Kazuo Matsuo, Fukusaburo Hamada, Sachio Tokiyoshi
-
Publication number: 20020183492Abstract: Multimers of human serum albumin are removed from a solution of human serum albumin containing the multimers by bringing the human serum albumin solution into contact with an anion-exchanger equilibrated with a buffer containing a salt in a concentration ranging from 10 to 150 mM and having a pH value ranging from 5 to 9.5.Type: ApplicationFiled: June 20, 2002Publication date: December 5, 2002Applicant: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Satoshi Adachi, Hiroshi Mizokami, Yoshitaka Tajima, Yoshinobu Miyatsu, Toshinobu Nouchi, Yoshitaka Ushio
-
Patent number: 6429286Abstract: An immunoregulatory molecule that regulates costimulatory signal transduction through interaction with the molecules involved in costimulatory signal transduction present on antigen presenting cells and/or T cells in the activation of T cells by antigen presenting cells and a process for preparing the same are provided. Said immunoregulatory molecule comprises a peptide which has two cysteine (Cys) residues forming Cys-Cys linkage and comprises at least six amino acid residues between said Cys-Cys linkage. Said immunoregulatory molecule is obtained by screening a phage random peptide library with a monoclonal antibody to CTLA-4 on T cells involved in costimulatory signal transduction.Type: GrantFiled: October 15, 1999Date of Patent: August 6, 2002Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventor: Kazuhisa Sugimura
-
Publication number: 20020031518Abstract: The present invention provides a plasminogen fragment with the activity to inhibit tumor metastasis and growth, a process for preparing said fragment and an agent for inhibiting tumor metastasis and growth comprising said fragment as an active ingredient. The plasminogen fragment of the present invention is prepared from a elastase lysate of Lys-Plasminogen, which is produced by treating a natural plasminogen with plasmin, and preferably exhibits a strong heparin binding activity. The agent for inhibiting tumor metastasis and growth comprising the plasminogen fragment as an active ingredient of the present invention is useful for clinically treating solid cancers such as lung cancer or colon cancer.Type: ApplicationFiled: November 21, 2001Publication date: March 14, 2002Applicant: Juridical Foundation the Chemo-Sero-Therapeutic Research InstituteInventors: Wataru Morikawa, Seiji Miyamoto
-
Patent number: 6300100Abstract: In a process for preparing Tissue Factor Pathway Inhibitor (TFPI) by the genetically engineered technique by the use of a transformed animal cell wherein a DNA encoding human TFPI is introduced, the improvement which comprises culturing said transformed animal cell in a culture medium supplemented with a sulfated polysaccharide to protect an intact TFPI produced by said transformed animal cell from cleavage by proteases present in the culture medium.Type: GrantFiled: June 28, 1994Date of Patent: October 9, 2001Assignee: Juridical Foundation the Chemo-Sero-Therapeutic Research InstituteInventors: Shintaro Kamei, Yuichi Kamikubo, Tsutomu Hamuro
-
Patent number: 6191113Abstract: A peptide comprising a peptide (A) of an amino acid sequence being abundant in basic amino acid residues and a peptide (B) of an amino acid sequence comprising at least two consecutive, hydrophobic amino acid residues wherein the peptide (B) is linked to the C-terminal of the peptide (A) directly or via several amino acid residues. The novel peptide of the present invention has the activity to inhibit growth of smooth muscle cells and a pharmaceutical composition comprising the peptide is useful for preventing or treating pathological conditions associated with growth of smooth muscle cells such as arteriosclerosis, restenosis after angioplasty, luminal stenosis after grafting blood vessel and smooth muscle sarcoma.Type: GrantFiled: April 24, 1998Date of Patent: February 20, 2001Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Yo Nakahara, Saburo Hara, Yuichi Kamikubo, Sumiyo Takemoto, Seiji Miyamoto
-
Patent number: 6139838Abstract: The present invention provides a t-PA medicinal preparation obtained by remarkably improving the solubility and stability of t-PA or modified t-PA. Nicotinamide or a derivative thereof is incorporated into t-PA or modified t-PA-containing solvent system. If necessary, a citrate buffer solution is also used. The t-PA-containing medicinal composition is in the form of, for example, a freeze-dried preparation.Type: GrantFiled: September 5, 1997Date of Patent: October 31, 2000Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Kazuyuki Nakashima, Yoshitaka Tajima, Shinichi Furukawa, Hiroshi Mizokami
-
Patent number: 6124432Abstract: The present invention aims at providing a method for preparing dermonecrotic toxin, an improved toxoid of dermonecrotic toxin produced by Bordetelia and a toxoid mixture comprising said improved toxoid of dermonecrotic toxin produced by Bordetella and a toxoid of dermonecrotic toxin produced by Pasteurella. There is provided a method for partially purifying dermonecrotic toxin which comprises bringing a dermonecrotic toxin-containing solution into contact with a chromatographic gel sulfated by direct sulfation or a chromatographic gel to which a sulfated molecule is covalently bonded to thereby make the dermonecrotic toxin adsorbed on the gel, and eluting the adsorbed dermonecrotic toxin from the gel.Type: GrantFiled: December 2, 1996Date of Patent: September 26, 2000Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Toru Kawai, Toshihiro Ushijima, Kozo Takase, Hideo Fujikawa
-
Patent number: 6114143Abstract: A monoclonal antibody useful for clinical application which recognizes the conserved region of V3-PND region of glycoprotein antigen having a molecular weight of about 1.2.times.10.sup.5 daltons (gp120) on a coating membrane of human immunodeficiency virus (HIV) and which has an ability to neutralize a broad range of various HIV variants, or a fragment thereof, and the chimeric and humanized antibodies derived therefrom are provided. By using as an immunogen a plurality of peptides having PND-Tip region containing the highly conserved GPGR sequence within PND of HIV gp120, a monoclonal antibody having a neutralizing activity to many HIV variants can be prepared. By transplanting the gene fragment coding for the variable region of said monoclonal antibody or complementarity determining region (CDR) of said region to a human antibody gene, a chimeric antibody or a reshaped antibody having an anti-HIV neutralizing activity which are effective for clinical application can be obtained.Type: GrantFiled: September 11, 1995Date of Patent: September 5, 2000Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Yasuyuki Eda, Hiroaki Maeda, Keiichi Makizumi, Kouichi Shiosaki, Kiyoshi Osatomi, Kazuhiko Kimachi, Hirofumi Higuchi, Sachio Tokiyoshi
-
Patent number: 6060449Abstract: There is provided an inhibitor of angiogenesis induced by growth of the vascular endothelial cells that comprises Tissue Factor Pathway Inhibitor (TFPI) as an active ingredient. The TFPI-containing preparation of the present invention can effectively inhibit angiogenesis induced by growth of the vascular endothelial cells, and thus, is quite efficacious for preventing and treating the conditions of diseases associated with angiogenesis such as malignant tumors.Type: GrantFiled: September 10, 1998Date of Patent: May 9, 2000Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Tsutomu Hamuro, Yo Nakahara, Sumiyo Takemoto, Seiji Miyamoto
-
Patent number: 6013261Abstract: A recombinant herpes virus is provided which efficiently expresses an exogenous protein of interest in an inoculated animal host to thereby endow the host with excellent immunization. A recombinant herpes virus which incorporates an exogenous gene expression cassette in which a herpes virus-derived gB gene (a gene homologous to herpes simplex virus gB gene) promoter is used as a promoter for expression of an exogenous gene.Type: GrantFiled: January 30, 1997Date of Patent: January 11, 2000Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Kengo Sonoda, Masashi Sakaguchi, Kazuo Matsuo, Fukusaburo Hamada
-
Patent number: 5962299Abstract: A method for stabilizing protein C or activated protein C and a preparation obtained by said method are provided, said method and preparation being applicable during procedures such as isolation and purification, lyophilization, heating, etc. or when stored.To a salt buffer containing protein C or activated protein C and sodium ion are added at least one amino acids, and further either one or a combination of albumin and a non-ionic surfactant.Type: GrantFiled: April 29, 1996Date of Patent: October 5, 1999Assignees: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute, Teijin LimitedInventors: Kazumasa Miyata, Yoshinori Akimoto, Yoichi Ogata, Tomohiro Nakagaki
-
Patent number: 5880274Abstract: A Gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of feline immunoglobulin .lambda. chain; a gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of feline immunoglobulin .kappa. chain; a gene fragment which comprises a DNA sequence coding for the constant region of feline immunoglobulin .gamma.Type: GrantFiled: November 17, 1995Date of Patent: March 9, 1999Assignee: Juridical Foundation, The Chemo-Sero-Therapeutic Research InstituteInventors: Hiroaki Maeda, Yasuyuki Eda, Kazuhiko Kimachi, Yoichi Ono, Sachio Tokiyoshi